Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene.
Multiple health benefits have been postulated for the long-term use of hormone therapy in postmenopausal women, most notably for prevention of osteoporotic fractures and coronary heart disease, as well as several risks, including cancer of the breast and uterus and venous thromboembolism. Cardiovascular disease is the most common cause of death among postmenopausal women. If real, the reduction in risk of coronary heart disease by hormone use suggested by observational studies would likely outweigh the risks. The decision to initiate and maintain hormone therapy is complicated by uncertainties about estrogen's true benefits and risks. Raloxifene, a selective estrogen receptor modulator (SERM), appears to have many of the benefits of estrogen without the cancer risks. It is not known if SERMs can provide significant cardiovascular protection. This article reviews the relation of use of postmenopausal hormones and raloxifene to women's health and addresses the need for large randomized trials to quantify the effect of both postmenopausal estrogen and raloxifene on cardiovascular health.
University of California, San Diego, La Jolla, USA.
E
E
Barrett-Connor
N K
NK
Wenger
D
D
Grady
L
L
Mosca
P
P
Collins
M
M
Kornitzer
D A
DA
Cox
E
E
Moscarelli
P W
PW
Anderson
D002318:Cardiovascular Diseases / Q000517:prevention & control; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000009:adverse effects / Q000819:agonists*; D005260:Female; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D017698:Postmenopause; D020849:Raloxifene Hydrochloride; D016032:Randomized Controlled Trials as Topic
D004967:Estrogens; D010880:Piperidines; D020849:Raloxifene Hydrochloride